Valuation: CorMedix Inc.

Capitalization 1.12B 973M 913M 832M 1.54B 97.26B 1.74B 10.82B 4.16B 44.62B 4.21B 4.12B 164B P/E ratio 2025 *
20.6x
P/E ratio 2026 * 11.9x
Enterprise value 976M 846M 793M 723M 1.34B 84.53B 1.52B 9.4B 3.62B 38.78B 3.66B 3.58B 143B EV / Sales 2025 *
6.74x
EV / Sales 2026 * 4.08x
Free-Float
99.03%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-3.14%
1 week+15.35%
Current month+32.45%
1 month+28.33%
3 months+49.30%
6 months+93.04%
Current year+98.52%
More quotes
1 week 13.37
Extreme 13.37
17.43
1 month 11.88
Extreme 11.88
17.43
Current year 5.6
Extreme 5.6
17.43
1 year 3.61
Extreme 3.61
17.43
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
18.8
10 years 0.86
Extreme 0.8605
26.4
More quotes
Manager TitleAgeSince
Chief Executive Officer 49 2022-05-09
Chief Executive Officer 48 2021-10-03
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 66 2015-08-05
Chairman 80 2017-08-02
Director/Board Member 69 2011-08-15
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-3.14%+15.35%+278.35%+366.09% 1.12B
+2.15%-0.36%-33.13%-32.22% 54.87B
+0.16%-0.48%-7.78%-17.88% 8.87B
+1.98%+1.66%+3.71%+15.12% 6.51B
+1.58%-3.39%+32.35%+107.38% 5.45B
+2.20%+1.09%+22.24%+32.52% 5.16B
+0.55%-10.51%+54.40%-6.07% 3.22B
-1.58%-2.83%+16.72%+10.60% 2B
+1.82%-1.48%-0.28%+16.41% 1.95B
+1.96%-1.13%-57.79%-13.33% 1.73B
Average +0.80%+0.60%+30.88%+47.86% 9.09B
Weighted average by Cap. +1.87%-2.85%-12.66%-7.19%
See all sector performances

Financials

2025 *2026 *
Net sales 145M 126M 118M 107M 199M 12.54B 225M 1.4B 537M 5.76B 544M 532M 21.2B 213M 185M 173M 158M 293M 18.45B 331M 2.05B 789M 8.47B 800M 783M 31.19B
Net income 56.05M 48.56M 45.54M 41.51M 76.96M 4.85B 87.06M 540M 208M 2.23B 210M 206M 8.2B 103M 89.24M 83.7M 76.29M 141M 8.92B 160M 992M 382M 4.09B 386M 378M 15.08B
Net Debt -147M -127M -119M -109M -202M -12.73B -228M -1.42B -545M -5.84B -552M -540M -21.52B -254M -220M -206M -188M -348M -21.95B -394M -2.44B -939M -10.07B -951M -931M -37.11B
More financial data * Estimated data
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Employees
65
More about the company
Date Price Change Volume
25-06-24 15.72 $ -5.07% 2,520,132
25-06-23 16.56 $ +21.68% 7,091,502
25-06-20 13.61 $ +0.22% 1,678,393
25-06-18 13.58 $ -2.58% 1,313,135
25-06-17 13.94 $ -2.79% 1,135,064

Delayed Quote Nasdaq, June 24, 2025 at 01:28 pm EDT

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
16.56USD
Average target price
17.50USD
Spread / Average Target
+5.68%
Consensus

Quarterly revenue - Rate of surprise